CTP-543 in moderate to severe alopecia areata

Phase 2, randomised, double-blind trial of deuruxolitinib in alopecia areata (4 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at 24 weeks and Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event at 28 weeks. Started Aug 2017; status: completed.